4.6 Review

The myth of 'stable' coronary artery disease

期刊

NATURE REVIEWS CARDIOLOGY
卷 17, 期 1, 页码 9-21

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41569-019-0233-y

关键词

-

资金

  1. Bayer
  2. Janssen Scientific Affairs

向作者/读者索取更多资源

Patients with known cardiovascular disease who have not had a recent acute event are often referred to as having stable coronary artery disease (CAD). The concept of 'stable' CAD is misleading for two important reasons: the continuing risks of cardiovascular events over the longer term and the diverse spectrum of powerful risk characteristics. The risks of cardiovascular events are frequently underestimated and continue to exist, despite current standards of care for secondary prevention, including lifestyle changes, optimal medical therapy, myocardial revascularization and the use of antiplatelet agents to limit thrombosis. In dispelling the myth of 'stable' CAD, we explore the pathophysiology of the disease and the relative contribution of plaque and systemic factors to cardiovascular events. A broader concept of the vulnerable patient, not just the vulnerable plaque, takes into account the diversity and future risks of atherothrombotic events. We also evaluate new and ongoing research into medical therapies aimed at further reducing the risks of cardiovascular events in patients with chronic - but not stable - atherothrombotic disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease

Yan Liang, Jun Zhu, Lisheng Liu, Sonia S. Anand, Stuart J. Connolly, Jackie Bosch, Tomasz J. Guzik, Martin O'Donnell, Gilles R. Dagenais, Keith Aa Fox, Olga Shestakovska, Scott D. Berkowitz, Eva Muehlhofer, Lars Keller, Salim Yusuf, John W. Eikelboom

Summary: In patients with stable coronary artery disease or peripheral artery disease, the combination of rivaroxaban (2.5 mg twice daily) and aspirin compared with aspirin alone appears to produce consistent benefits in women and men, independent of baseline cardiovascular risk. There was no significant interaction between randomized treatment and baseline cardiovascular risk for major adverse cardiovascular events or major bleeding.

CARDIOVASCULAR RESEARCH (2021)

Article Cardiac & Cardiovascular Systems

Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction

John Hung, Andreas Roos, Erik Kadesjo, David A. McAllister, Dorien M. Kimenai, Anoop S. Shah, Atul Anand, Fiona E. Strachan, Keith A. A. Fox, Nicholas L. Mills, Andrew R. Chapman, Martin J. Holzmann

Summary: The GRACE 2.0 score showed good discrimination for predicting all-cause death at 1 year in patients with type 1 myocardial infarction, but only moderate discrimination for those with type 2 myocardial infarction.

EUROPEAN HEART JOURNAL (2021)

Article Cardiac & Cardiovascular Systems

2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group

Francois Schiele, Suleman Aktaa, Xavier Rossello, Ingo Ahrens, Marc J. Claeys, Jean-Philippe Collet, Keith A. A. Fox, Chris P. Gale, Kurt Huber, Zaza Iakobishvili, Alan Keys, Ekaterini Lambrinou, Sergio Leonardi, Maddalena Lettino, Frederick A. Masoudi, Susanna Price, Tom Quinn, Eva Swahn, Holger Thiele, Adam Timmis, Marco Tubaro, Christiaan J. M. Vrints, David Walker, Hector Bueno, Sigrun Halvorsen, Tomas Jernberg, Jarle Jortveit, Mai Blondal, Borja Ibanez, Christian Hassager

Summary: Updated quality indicators for the management of acute myocardial infarction were developed based on contemporary knowledge and accumulated experience, aiming to evaluate and improve the quality of care for myocardial infarction.

EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE (2021)

Article Cardiac & Cardiovascular Systems

Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial

Matthew A. Cavender, Michelle L. O'Donoghue, Antonio Abbate, Philip Aylward, Keith Aa Fox, Ruchira X. Glaser, Jeong-Gun Park, Jose Lopez-Sendon, Ph Gabriele Steg, Marc S. Sabatine, David A. Morrow

Summary: Losmapimod attenuated inflammatory response in patients with STEMI but not in those with NSTEMI. Differences in outcomes between the two patient groups suggest a potential need for separate strategies in managing inflammation in MI, with a stronger focus on heart failure.

AMERICAN HEART JOURNAL (2022)

Article Cardiac & Cardiovascular Systems

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials

Sonia S. Anand, Will Hiatt, Leanne Dyal, Rupert Bauersachs, Scott D. Berkowitz, Kelley R. H. Branch, Sebastian Debus, Keith A. A. Fox, Yan Liang, Eva Muehlhofer, Mark Nehler, Lloyd P. Haskell, Manesh Patel, Michael Szarek, Salim Yusuf, John Eikelboom, Marc P. Bonaca

Summary: Among peripheral artery disease (PAD) patients, low-dose rivaroxaban plus aspirin is superior to aspirin alone in reducing cardiovascular and limb events, including acute limb ischemia and major vascular amputation. Despite an increased risk of major bleeding, there is no significant increase in severe bleeding with the combination therapy.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Letter Cardiac & Cardiovascular Systems

Beta-blockers in acute coronary syndrome patients: The concept of 'gradient of benefit'

Fernando Montenegro Sa, Joao Moraisb

REVISTA PORTUGUESA DE CARDIOLOGIA (2021)

Article Cardiac & Cardiovascular Systems

Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper

Jose Silva-Cardoso, Candida Fonseca, Fatima Franco, Joao Morais, Jorge Ferreira, Dulce Brito

Summary: The Portuguese HF expert panel contributed to the ongoing debate regarding HFrEF management by highlighting three key principles: the preference for sacubitril/valsartan as first-line therapy, the importance of four foundation HFrEF drugs regardless of diabetes status, and the introduction and dose up-titration of these drugs over specific timeframes guided by a safety protocol.

REVISTA PORTUGUESA DE CARDIOLOGIA (2021)

Article Cardiac & Cardiovascular Systems

GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation

Keith A. A. Fox, Saverio Virdone, Karen S. Pieper, Jean-Pierre Bassand, A. John Camm, David A. Fitzmaurice, Samuel Z. Goldhaber, Shinya Goto, Sylvia Haas, Gloria Kayani, Ali Oto, Frank Misselwitz, Jonathan P. Piccini, Frederik Dalgaard, Alexander G. G. Turpie, Freek W. A. Verheugt, Ajay K. Kakkar

Summary: This study confirms the effectiveness of the GARFIELD-AF integrated risk tool in predicting mortality, stroke, and bleeding in patients with atrial fibrillation, and compares it with the traditional predictors CHA(2)DS(2)-VASc and HAS-BLED.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2022)

Article Medicine, General & Internal

Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry

Keith A. A. Fox, Saverio Virdone, Jean-Pierre Bassand, A. John Camm, Shinya Goto, Samuel Z. Goldhaber, Sylvia Haas, Gloria Kayani, Yukihiro Koretsune, Frank Misselwitz, Seil Oh, Jonathan P. Piccini, Alex Parkhomenko, Jitendra Pal Singh Sawhney, Janina Stepinska, Alexander G. G. Turpie, Freek W. A. Verheugt, Ajay K. Kakkar

Summary: The variability in outcomes for patients with newly diagnosed AF across countries cannot be explained by baseline characteristics and antithrombotic treatments. Mortality rates are correlated with Healthcare Access and Quality indices.

BMJ OPEN (2022)

Letter Cardiac & Cardiovascular Systems

Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis

Nana Pogosova, Jacqueline Bosch, Deepak L. Bhatt, Keith A. A. Fox, Stuart J. Connolly, Marco Alings, Peter Verhamme, Eva Muehlhofer, Olga Shestakovska, Salim Yusuf, John W. Eikelboom

CIRCULATION (2022)

Editorial Material Cardiac & Cardiovascular Systems

Acute coronary syndrome in a young patient with a single coronary artery

Sara I. L. Fernandes, Luis M. G. Santos, Maria F. A. Saraiva, Jose A. S. Antunes, Helia A. F. Martins, Joao C. A. Morais

CORONARY ARTERY DISEASE (2022)

Review Cardiac & Cardiovascular Systems

Acute, periprocedural and longterm antithrombotic therapy in older adults 2022 Update by the ESC Working Group on Thrombosis

Felicita Andreotti, Tobias Geisler, Jean-Philippe Collet, Bruna Gigante, Diana A. Gorog, Sigrun Halvorsen, Gregory Y. H. Lip, Joao Morais, Eliano Pio Navarese, Carlo Patrono, Bianca Rocca, Andrea Rubboli, Dirk Sibbing, Robert F. Storey, Freek W. A. Verheugt, Gemma Vilahur

Summary: This study aims to provide a concise yet comprehensive tool for understanding the bases of antithrombotic therapy in older patients, considering the complexities of comorbidities, comedications, and the uncertain balance between ischemic and bleeding risks.

EUROPEAN HEART JOURNAL (2023)

Letter Cardiac & Cardiovascular Systems

Letter to the Editor regarding Suboptimal control of cardiovascular risk factor control in myocardial infarction survivors in a cardiac rehabilitation program

Alexandre Antunes, Margarida Cabral, Joao Morais

REVISTA PORTUGUESA DE CARDIOLOGIA (2023)

Article Cardiac & Cardiovascular Systems

Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Josephine Harrington, Anthony P. Carnicelli, Kaiyuan Hua, Lars Wallentin, Manesh R. Patel, Stefan H. Hohnloser, Robert P. Giugliano, Keith A. A. Fox, Ziad Hijazi, Renato D. Lopes, Sean D. Pokorney, Hwanhee Hong, Christopher B. Granger

Summary: Through meta-analysis of multiple research databases, it was found that standard-dose DOACs are safer and more effective than warfarin in patients with kidney dysfunction. While lower-dose DOACs do not significantly lower the incidence of bleeding or intracranial hemorrhage compared to standard-dose DOACs, they are associated with a higher incidence of stroke and systemic embolism as well as death. Therefore, these findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.

CIRCULATION (2023)

Editorial Material Cardiac & Cardiovascular Systems

Towards personalized cardiovascular care: Global Registry of Acute Coronary Events 3.0 score heralds artificial intelligence era

Florian A. Wenzl, Keith A. A. Fox, Thomas F. Luescher

EUROPEAN HEART JOURNAL (2023)

暂无数据